Cargando…
Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg)
Background: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxic...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225562/ https://www.ncbi.nlm.nih.gov/pubmed/35743627 http://dx.doi.org/10.3390/jcm11123544 |
_version_ | 1784733643751555072 |
---|---|
author | Fernández-Salazar, Luis Campillo, Ana Rodrigo, Luis Pérez-Aisa, Ángeles González-Santiago, Jesús M. Segarra Ortega, Xavier Denkovski, Maja Brglez Jurecic, Natasa Bujanda, Luis Gómez Rodríguez, Blas José Ortuño, Juan Georgopoulos, Sotirios Jonaitis, Laimas Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier P. |
author_facet | Fernández-Salazar, Luis Campillo, Ana Rodrigo, Luis Pérez-Aisa, Ángeles González-Santiago, Jesús M. Segarra Ortega, Xavier Denkovski, Maja Brglez Jurecic, Natasa Bujanda, Luis Gómez Rodríguez, Blas José Ortuño, Juan Georgopoulos, Sotirios Jonaitis, Laimas Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier P. |
author_sort | Fernández-Salazar, Luis |
collection | PubMed |
description | Background: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results. Methods: An international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult cases treated with HDDT were registered at e-CRF AEG-REDCap platform until June 2021. Sixty patients were prescribed with HDDT (98% compliance), 19 of them received a first-line therapy and 41 a rescue treatment (second- to sixth-line). Results: Overall HDDT effectiveness was 52% (per-protocol) and 51% (modified intention-to-treat). First-line and rescue treatment lines were equally effective, but the effectiveness was worse when patients had previously received metronidazole, tetracycline, or rifabutin. Adding bismuth to HDDT in rescue treatment did not yield better results. The incidence of adverse events was 30%, diarrhea being the most common (20% of patients); no serious adverse events were reported. Conclusion: Although HDDT is safe and has good compliance, it is not a good option in European first-line or rescue H. pylori treatment, even when adding bismuth. |
format | Online Article Text |
id | pubmed-9225562 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92255622022-06-24 Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg) Fernández-Salazar, Luis Campillo, Ana Rodrigo, Luis Pérez-Aisa, Ángeles González-Santiago, Jesús M. Segarra Ortega, Xavier Denkovski, Maja Brglez Jurecic, Natasa Bujanda, Luis Gómez Rodríguez, Blas José Ortuño, Juan Georgopoulos, Sotirios Jonaitis, Laimas Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier P. J Clin Med Article Background: Randomized clinical trials and meta-analyses, primarily from Asian countries, have reported good effectiveness with high-dose dual therapy (HDDT) including a proton pump inhibitor (PPI) and amoxicillin when prescribed as H. pylori first-line or rescue treatment. However, combining amoxicillin with PPIs in the 1990s in several European countries yielded suboptimal results. Methods: An international, multicenter, prospective non-interventional Registry (Hp-EuReg) aimed to evaluate the decisions and outcomes of H. pylori management by European gastroenterologists. All infected adult cases treated with HDDT were registered at e-CRF AEG-REDCap platform until June 2021. Sixty patients were prescribed with HDDT (98% compliance), 19 of them received a first-line therapy and 41 a rescue treatment (second- to sixth-line). Results: Overall HDDT effectiveness was 52% (per-protocol) and 51% (modified intention-to-treat). First-line and rescue treatment lines were equally effective, but the effectiveness was worse when patients had previously received metronidazole, tetracycline, or rifabutin. Adding bismuth to HDDT in rescue treatment did not yield better results. The incidence of adverse events was 30%, diarrhea being the most common (20% of patients); no serious adverse events were reported. Conclusion: Although HDDT is safe and has good compliance, it is not a good option in European first-line or rescue H. pylori treatment, even when adding bismuth. MDPI 2022-06-20 /pmc/articles/PMC9225562/ /pubmed/35743627 http://dx.doi.org/10.3390/jcm11123544 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fernández-Salazar, Luis Campillo, Ana Rodrigo, Luis Pérez-Aisa, Ángeles González-Santiago, Jesús M. Segarra Ortega, Xavier Denkovski, Maja Brglez Jurecic, Natasa Bujanda, Luis Gómez Rodríguez, Blas José Ortuño, Juan Georgopoulos, Sotirios Jonaitis, Laimas Puig, Ignasi Nyssen, Olga P. Megraud, Francis O’Morain, Colm Gisbert, Javier P. Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg) |
title | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter
pylori Infection (Hp-EuReg) |
title_full | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter
pylori Infection (Hp-EuReg) |
title_fullStr | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter
pylori Infection (Hp-EuReg) |
title_full_unstemmed | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter
pylori Infection (Hp-EuReg) |
title_short | Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter
pylori Infection (Hp-EuReg) |
title_sort | effectiveness and safety of high-dose dual therapy: results of the european registry on the management of helicobacter
pylori infection (hp-eureg) |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225562/ https://www.ncbi.nlm.nih.gov/pubmed/35743627 http://dx.doi.org/10.3390/jcm11123544 |
work_keys_str_mv | AT fernandezsalazarluis effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT campilloana effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT rodrigoluis effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT perezaisaangeles effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT gonzalezsantiagojesusm effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT segarraortegaxavier effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT denkovskimaja effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT brglezjurecicnatasa effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT bujandaluis effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT gomezrodriguezblasjose effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT ortunojuan effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT georgopoulossotirios effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT jonaitislaimas effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT puigignasi effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT nyssenolgap effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT megraudfrancis effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT omoraincolm effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg AT gisbertjavierp effectivenessandsafetyofhighdosedualtherapyresultsoftheeuropeanregistryonthemanagementofhelicobacterpyloriinfectionhpeureg |